Ionis Pharmaceuticals, Inc. (IONS)
IONS moved a median of +0.02% 30 minutes after news, and 0.00% by the close. How IONS actually reacts to news — the realized, point-in-time move the market made, measured across 811 labeled events over the last three years with zero look-ahead.
IONS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.05% | 46% | 799 |
| 30-min | +0.02% | 52% | 800 |
| 60-min | -0.04% | 46% | 800 |
| to close | 0.00% | 49% | 804 |
| Middle 50% of IONS reactions | -0.60% to +0.69% |
|---|---|
| Median reaction (30-min) | +0.02% |
| Measured reactions | 811 |
Half of all Ionis Pharmaceuticals, Inc. news events land between -0.60% and +0.69% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How IONS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 46 | -0.24% | 39% | +0.05% |
| Analyst downgrades | 12 | -0.27% | 50% | -0.63% |
| Coverage initiations | 24 | -0.48% | 46% | +0.24% |
| Rating reiterations | 199 | +0.06% | 52% | -0.03% |
| Price-target raises | 56 | -0.14% | 43% | -0.27% |
| Price-target cuts | 20 | -0.05% | 45% | -0.54% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how IONS ranks against every other measured name →
That’s how IONS usually reacts — get an email when it moves on news →Email me when IONS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IONS's baseline. Nothing else.
Recent IONS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG) | Press release | Business Wire | -1.86% | -3.57% | |
| Form 8-K IONIS PHARMACEUTICALS For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | -1.93% | -4.97% | |
| Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN) | Press release | Business Wire | -1.93% | -4.97% | |
| Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS | Press release | Business Wire | -0.84% | +1.76% | |
| Form 8-K IONIS PHARMACEUTICALS For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | -0.27% | -0.46% | |
| Form 8-K IONIS PHARMACEUTICALS For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | +2.54% | +8.02% | |
| Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) | Press release | Business Wire | +2.54% | +8.02% | |
| Ionis to present at upcoming investor conferences | Press release | Business Wire | -2.81% | -3.79% | |
| ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients | Press release | Business Wire | -0.27% | -0.46% | |
| Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 | Press release | Business Wire | -0.32% | -2.07% | |
| IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law | Press release | Business Wire | +0.77% | — | |
| Form S-8 IONIS PHARMACEUTICALS | SEC filing · Form S-8 | SEC EDGAR | +0.08% | +0.25% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ionis Pharmaceuticals, Inc. (IONS) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.07% | -1.94% | |
| Form 10-Q IONIS PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.41% | -1.19% | |
| Form 8-K IONIS PHARMACEUTICALS For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | -1.62% | -1.76% | |
| Ionis announces Dr. Frank Bennett, chief scientific officer, to retire | Press release | Business Wire | -1.62% | -1.76% | |
| Ionis reports second quarter 2026 financial results and highlights progress on key programs | Press release | Business Wire | -1.62% | -1.76% | |
| Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS | Press release | GlobeNewswire | +0.06% | +0.99% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Ionis Pharmaceuticals, Inc. (IONS) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.11% | -1.04% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Ionis Pharmaceuticals, Inc. (IONS) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.09% | -1.13% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Ionis Pharmaceuticals, Inc. (IONS) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.65% | -2.60% | |
| Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS | Press release | PR Newswire | -0.18% | -1.49% | |
| Ionis Pharmaceuticals, Inc. (IONS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.17% | +0.26% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ionis Pharmaceuticals, Inc. (IONS) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.04% | -2.72% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Ionis Pharmaceuticals, Inc. (IONS) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.13% | +0.32% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ionis Pharmaceuticals, Inc. (IONS) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -0.17% | +1.05% | |
| Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS | Press release | GlobeNewswire | -0.70% | +1.20% | |
| Ionis to hold second quarter 2026 financial results webcast | Press release | Business Wire | -0.79% | +0.46% | |
| Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease | Press release | Business Wire | +0.24% | -1.56% | |
| Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS | Press release | GlobeNewswire | -0.22% | -0.40% | |
| Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome | Press release | Business Wire | -1.40% | -2.00% | |
| Form 8-K IONIS PHARMACEUTICALS For: Jul 09 | SEC filing · Form 8-K | SEC EDGAR | -7.24% | -9.37% | |
| Form 8-K IONIS PHARMACEUTICALS For: Jul 09 | SEC filing · Form 8-K | SEC EDGAR | -0.36% | -0.43% | |
| Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy | Press release | Business Wire | +1.47% | -4.45% | |
| Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome | Press release | Business Wire | -0.60% | +1.30% | |
| Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S. | Press release | Business Wire | +0.29% | +2.15% | |
| Form 8-K IONIS PHARMACEUTICALS For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | -0.25% | -0.68% | |
| TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG) | Press release | Business Wire | +0.08% | -0.66% | |
| Form 8-K IONIS PHARMACEUTICALS For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | -0.04% | +0.03% | |
| Form 8-K IONIS PHARMACEUTICALS For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -0.14% | -0.23% | |
| Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors | Press release | Business Wire | -0.53% | -1.06% | |
| Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses | Press release | Business Wire | -0.22% | +1.51% | |
| Form 8-K IONIS PHARMACEUTICALS For: May 28 | SEC filing · Form 8-K | SEC EDGAR | -0.04% | -0.36% | |
| Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B | Press release | Business Wire | -1.32% | +0.98% | |
| Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease | Press release | Business Wire | -0.94% | -4.20% | |
| Ionis to host 2026 virtual Annual Meeting of Stockholders | Press release | Business Wire | +0.13% | +0.23% | |
| Ionis to present at upcoming investor conferences | Press release | Business Wire | -0.31% | +0.56% | |
| Form 10-Q IONIS PHARMACEUTICALS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.33% | +1.59% | |
| Form 8-K IONIS PHARMACEUTICALS For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | -0.25% | +3.84% | |
| Ionis reports first quarter 2026 financial results and highlights progress on key programs | Press release | Business Wire | -0.25% | +3.84% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IONS section they belong to.
Where else IONS is measured.
IONS earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Sinovac Biotech, Ltd. - Ordinary Shares (Antigua/Barbudo) (SVA) | 814 | 0.00% | 46% |
| Atara Biotherapeutics, Inc. (ATRA) | 813 | -0.27% | 45% |
| Applied Genetic Technologies Corporation (AGTC) | 805 | 0.00% | 45% |
| KERYX BIOPHARMACEUTICALS (KERX) | 804 | 0.00% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Ionis Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled IONS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 811 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of IONS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IONS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.